Biological immunomodulators improve the healing rate in surgically treated perianal Crohn's fistulas

Colorectal Disease

Volumn 14, Issue 10, 2012, Pages 1217-1223

  El Gazzaz, G ^a   Hull, T ^a   Church, J M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biologics; Crohn's disease; Immunomodulators; Perianal fistula

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; STEROID;

ADULT; AGE; ANUS FISTULA; ARTICLE; BODY MASS; CIGARETTE SMOKING; CROHN DISEASE; DRUG RESPONSE; FEMALE; FISTULOTOMY; FOLLOW UP; GRANULOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PERIANAL CROHN FISTULA; PRIORITY JOURNAL; RECTUM ADVANCEMENT FLAP; RECTUM SURGERY; SETON DRAINAGE; SURGICAL DRAINAGE; SURGICAL TECHNIQUE; TISSUE FLAP; WOUND HEALING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOTHERAPY, ADJUVANT; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECTAL FISTULA; RECTUM; TREATMENT OUTCOME; WOUND HEALING;

EID: 84866405562     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2012.02944.x     Document Type: Article

References (24)

1. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn's disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg 2002; 137: 774-7.
2. Fry RD, Shemesh EI, Kodner IJ, Timmcke A. Techniques and results in the management of anal and perianal Crohn's disease. Surg Gynecol Obstet 1989; 168: 42-8.
3. El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M. Analysis of function and predictors of failure in women undergoing repair of crohn's related rectovaginal fistula. J Gastrointest Surg 2010; 14: 824-9.
4. Rankin GB, Watts HD, Melnyk CS, Kelley ML. National Cooperative Crohn's DiseaseStudy: extraintestinal manifestations and perianal complications. Gastroenterolog 1979; 77: 914-20.
5. American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 2003; 125: 1503-7.
6. Figg RE, Church JM. Perineal Crohn's disease: an indicator of poor prognosis and potential proctectomy. Dis Colon Rectum 2009; 52: 646-50.
7. Scott NA, Nair A, Hughes LE. Anovaginal and rectovaginal fistula in patients with Crohn's disease. Br J Surg 1992; 79: 1379-80.
8. Schwartz DA, Loftus EV Jr, Tremaine WJ et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-80.
9. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30.
10. Morrison JG, Gathright JB, Ray JE, Ferrari BT, Hicks TC, Timmcke AE. Results of operation for rectovaginal fistula in Crohn's disease. Dis Colon Rectum 1989; 32: 497-9.
11. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
12. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis 2005; 7: 164-8.
13. Van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005; 48: 758-67.
14. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
15. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
16. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46: 577-83.
17. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-41.
18. Gaertner WB, Decanini A, Mellgren A et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007; 50: 1754-60.
19. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn_s disease and associated fistulae. Am J Gastroenterol 1984; 79: 533-40.
20. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn_s disease. Gastroenterology 1990; 99: 1347-51.
21. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pastermack BS. Treatment of Crohn's disease with 6-Mercaptopurine. A long-term randomized trial, double-blind study. N Eng J Med 1980; 302: 981-7.
22. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39: 374-80.
23. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gatroenterol 1993; 88: 646-9.
24. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment refractory Crohn_s disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 239-45.